Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Approved and future pharmacotherapy for multiple sclerosis.

Olaf Stüve1, Bruce C Cree, Hans-Christian von Büdingen

  • 1Department of Neurology, University of California, San Francisco 94143-0114, USA. ostuve@itsa.ucsf.edu

The Neurologist
|June 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease outcomes with ublituximab in treatment-naïve participants: subpopulation analyses of the phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis.

Frontiers in immunology·2026
Same author

C1-esterase Inhibitor Treatment is Associated with Immune and Vascular Pathway Modulation in PASC with Neurological Symptoms: Longitudinal Plasma Proteomics.

Cellular and molecular neurobiology·2026
Same author

Peripheral complement C4 protein in schizophrenia: Association with gene copy number and immune cell subtypes.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Why Is MS a More Frequent Complication of EBV Infection in Females?

Immunological reviews·2026
Same author

Cytotoxic T cell recognition of α-synuclein drives pathogenic immune responses in multiple system atrophy.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Postural Orthostatic Tachycardia Syndrome, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID as Neuroimmune Disorders.

ImmunoTargets and therapy·2026
Same journal

Artificial Intelligence in the Prehospital Stage of Stroke: Can Virtual Assistants Optimize Triage?

The neurologist·2026
Same journal

Looking Beyond the Midline: An Uncommon Etiology of Internuclear Ophthalmoplegia of Abduction Due to Cerebral Venous Thrombosis.

The neurologist·2026
Same journal

Commentary: Cervical Artery Dissection and Chiropractic Cervical Manipulation: Clarifying Association, Mechanism, and Interpretation.

The neurologist·2026
Same journal

Acute Spinal Cord Infarct Secondary to Fibrocartilaginous Embolism Treated With Tenecteplase.

The neurologist·2026
Same journal

Cervical Artery Dissection and Chiropractic​​​​​.

The neurologist·2026
Same journal

Oromandibular Dyskinesia Associated With Levofloxacin and Responsive to Low-Dose Oral Diazepam: A Case Report.

The neurologist·2026
See all related articles

Current multiple sclerosis (MS) treatments like interferon beta and glatiramer acetate show partial effectiveness. Statins, a safe oral medication class, may offer a new therapeutic avenue for MS patients and warrant further clinical investigation.

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Relapsing-remitting multiple sclerosis (MS) treatment has advanced with interferon beta and glatiramer acetate.
  • Mitoxantrone is approved for secondary progressive MS, but current therapies have limitations.
  • Oral immunomodulatory agents are under evaluation, with statins showing promise due to safety and tolerability.

Purpose of the Study:

  • To review clinical evidence for approved multiple sclerosis (MS) therapies.
  • To discuss the mechanisms of action for existing MS treatments.
  • To explore the potential role of statins in MS therapy based on clinical and laboratory data.

Main Methods:

  • Review of clinical evidence for approved multiple sclerosis (MS) therapies.
  • Discussion of mechanisms of action for interferon beta, glatiramer acetate, and mitoxantrone.

Related Experiment Videos

  • Analysis of clinical and laboratory data regarding statin use in MS.

    • Main Results:

    • Approved MS therapies, including interferon beta, glatiramer acetate, and mitoxantrone, offer treatment options.
    • Statins are safe, well-tolerated, and represent a potential new class of MS therapeutics.
    • Existing treatments for MS are only partially effective and may have significant side effects.

    Conclusions:

    • Interferon beta, glatiramer acetate, and mitoxantrone are important treatments for relapsing-remitting MS and secondary progressive MS.
    • The potential benefits of statins in multiple sclerosis (MS) therapy require further exploration.
    • Controlled clinical trials are necessary to evaluate the efficacy of statins and other potential MS medications.